Figure 4.

The Mouse PDX model was used to evaluate the reliability of MTAM PDX system (a) HT29 cancer cell line were injected into mouse model to establish a tumor, and this mice is treated as a ‘patient’. The resulting tumor were extracted and divided into two, where one part was utilized in the MTAM-based HFA system and the other in a standard xenograft model to serve as a benchmark. (b) Growth inhibition of primary HT29 cells in the MTAM implanted s.c. in mice. Drugs were administrated once daily by i.v. injection from days 3–7 after implantation. (c) Nude mice bearing 100 mm³ xenografts were randomized into treatment groups, Tumor volume of mice bearing primary HT29 xenografts was measured every other day. Both (b) and (c) appeared to provide similar screening outcome trend and to a certain extent comparable outcome, which suggested that the MTAM PDX system was capable of producing similar outcome when compared to the current gold standard (traditional xenograft) Student’s t-test; P < 0.05.